Pharmaceutical Market Europe • May 2023 • 46-48
APPOINTMENTS
Amarin
Aaron Berg
Amarin has appointed Aaron Berg as interim president and chief executive officer. Berg, who is currently Amarin’s executive vice president, joined the company in 2012. He initially served as vice president, marketing and managed care. He was promoted to senior vice president, marketing and sales, and then to the position of senior vice president and chief commercial officer. Before joining Amarin, Berg served as president and chief executive officer for Essentialis, a development stage pharmaceutical company, where he led its work on triglyceride management. Prior to this, Berg was vice president of marketing and sales at Kos Pharmaceuticals, until it was acquired by Abbott Laboratories in 2006. Before joining Kos, Berg began his career in pharma as a sales representative with Bristol Myers Squibb, followed by ten years at Schering-Plough, before joining GSK.
Abivax SA
Marc de Garidel
Abivax SA has appointed Marc de Garidel as chief executive officer and interim board chair. Garidel brings extensive industry experience to the role. He was most recently CEO at CinCor Pharma, and held the same position at Ipsen, AZTherapies and Cordvidia Therapeutics. Prior to that, he worked at Amgen and Eli Lilly in a variety of roles. He has served as chairman of the board of Ipsen since 2010.
FogPharma
Mathai Mammen
FogPharma has appointed Mathai Mammen as chief executive officer, president and chairman. Mammen brings significant global R&D and leadership experience to the role, having most recently served as executive vice president, pharmaceuticals, R&D, at Johnson & Johnson. Prior to that, he held senior R&D roles at Merck, having begun his career as head of R&D at Theravance, a company he co-founded out of graduate school.
Engimmune Therapeutics
Lars Nieba
Engimmune Therapeutics AG has appointed Lars Nieba as chief executive officer. Nieba joins the company with more than 25 years of experience in biopharma leadership roles, having been CEO and a scientific advisor to a number of biotech companies. He was recently CEO and chief technology officer at Nordic Nanovector ASA and has held positions at Roche, Bayer, Pureos Bioventures and TEMAS AG.
AiCuris AG
Larry Edwards
AiCuris AG has appointed Larry Edwards as chief executive officer. Edwards brings more than two decades of experience in executive and commercial leadership roles in the anti-infective space to his new position. He most recently served as president and CEO of La Jolla Pharmaceuticals. Prior to that, he was CEO of Tetraphase Pharmaceuticals and has held a variety of roles at Cubist Pharmaceuticals and Merck & Co.
Biogen
Caroline Dorsa
Biogen has appointed Caroline Dorsa as chair of its board of directors. Dorsa originally joined the company’s board in 2010. She was most recently executive vice president and chief financial officer of Public Service Enterprise Group from 2009 until her retirement in 2015. Prior to that, she held various positions over her 21 years at Merck & Co, including senior vice president, global human health, strategy and integration.
Medicon Valley Alliance
Niels Abel Bonde
Medicon Valley Alliance has appointed Niels Abel Bonde as chairman of its board of directors. Bonde currently serves as general manager of Novo Nordisk, Sweden. Prior to that, he was the company's marketing director, diabetes. He is also a member of the boards of SwedenBIO and The Swedish Association of the Pharmaceutical Industry. Prior to joining Novo Nordisk in 2011, Bonde was business unit director at GSK.
Regeneron Pharmaceuticals
Leonard Schleifer
Regeneron Pharmaceuticals has appointed Leonard Schleifer as co-chair of its board of directors. Schleifer founded the company in 1988 and will continue to serve as its president and chief executive officer. He has also been a clinical professor of neurology and neuroscience at Weill Cornell Medical College, and was elected as a fellow by the American Association for the Advancement of Science in 2019.
Regeneron Pharmaceuticals
George Yancopoulos
Regeneron Pharmaceuticals has appointed George Yancopoulos as co-chair of its board of directors. Yancopoulos has built and managed the company alongside Leonard Schleifer since 1989 and will continue to serve as president and chief scientific officer. In 2004, he was elected to the National Academy of Sciences, and in 2014 as a fellow for the American Association for the Advancement of Science.
BeiGene
Julius Pryor
BeiGene has appointed Julius Pryor III as its first global head of diversity and health equity. Pryor has more than 30 years of experience in diversity, equity, inclusion and belonging (DEI&B) efforts, having built DEI&B programmes for biotech companies and global consumer-focused businesses. Pryor joins BeiGene from the J. Pryor Group, where he served as a general managing partner. Over the course of his career, Pryor has also held executive roles at Johnson & Johnson, Genentech, Coca-Cola Enterprises, Russell Athletic, Abbott, Takeda and Cerner. He is also chair of the board of directors at the Center for Healthcare Innovation. DEI is a relatively new area of focus for BeiGene, which set up a DEI and awareness council in the US in 2020. This has since been expanded beyond the US. In his newly created role, Pryor will lead the company's efforts to elevate its health equity and DEI&B initiatives.
Ipsen
Sandra Silvestri
Ipsen has appointed Sandra Silvestri as executive vice president, chief medical officer and head of global medical affairs, patient safety and patient affairs. Silvestri brings years of extensive medical experience in the global biopharma industry to the role and joins Ipsen after spending eight years at Sanofi. She has also held numerous roles at Eli Lilly across R&D and scientific communications, and as regional medical director.
Terns Pharmaceuticals
Emil Kuriakose
Terns Pharmaceuticals has appointed Emil Kuriakose as chief medical officer, oncology. Kuriakose brings more than a decade of clinical development and medical affairs experience to his new role. He joins the company from Calithera Biosciences, where he was most recently chief medical officer. Prior to this, he was global clinical programme lead at Novartis Institutes for BioMedical Research.
Breye Therapeutics ApS
Peter Adamson
Breye Therapeutics ApS has appointed Peter Adamson as chief scientific officer. Adamson joins the company with over 20 years of experience in ophthalmology drug development. Over the course of his career, he has held various senior leadership positions at a range of biopharma companies, including vice president and head of ophthalmology research at GSK. He has also worked at ProQR and Tenpoint Therapeutics.
SynAct Pharma AB
Torbjørn Bjerke
SynAct Pharma AB has appointed Torbjørn Bjerke as chief executive officer. Bjerke will leave his position as partner and portfolio manager at Arctic Asset Management and continue to serve on the boards of Arctic Aurora Life Science, Biotech Select, Biothea and Carelight. He was previously president and CEO of Karolinska Development AB, Orexo AB and Biolipox AB, and has also worked at ALK Abello.
Sanofi
Elisabeth Moreno
Sanofi has appointed Elisabeth Moreno to its diversity, equity and inclusion board. Moreno has worked in various industries and international environments, such as France Télécom (now Orange), Dell and Lenovo. She was recently lead for the African continent organisation at Hewlett Packard, and was appointed as minister for gender equality, diversity and equal opportunities in the French government.
Breye Therapeutics ApS
Gabriela Burian
Breye Therapeutics ApS has appointed Gabriela Burian to its board of directors. Burian brings more than 25 years of experience in clinical research and drug development in ophthalmology to the role. She has previously held global leadership positions at biopharmas including Roche and Novartis, and will now support Breye's management team as it builds its retinal vascular diseases pipeline.
Chinook Therapeutics
Robert Azelby
Chinook Therapeutics has appointed Robert Azelby to its board of directors. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to the company. Most recently, he served as president and chief executive officer of Eliem Therapeutics. He has also previously held roles at Alder BioPharmaceuticals, Juno Therapeutics and Amgen.
NRG Therapeutics
Jonathan Savidge
NRG Therapeutics has appointed Jonathan Savidge as independent non-executive chair of its board of directors. Savidge brings over 20 years of industry experience to the role and currently serves as chief executive officer of Kynos Therapeutics. Prior to this, Savidge was founding CEO of Syndesi Therapeutics and held senior business and corporate development roles at Evotec and Proximagen.
Havas Health & You
Sangeeta Barde
Havas Health & You has appointed Sangeeta Barde as Havas Life Sorento’s regional head of Middle East and chief executive officer of India. Barde has held a variety of senior leadership roles within the agency and was most recently managing director. She was also the founding director of the Organization for Rare Diseases in India, which aims to raise awareness and understanding of rare diseases.
Havas Health & You
Jini Mathai
Havas Health & You has appointed Jini Mathai as regional head of Southeast Asia. Mathai has nearly two decades of experience providing guidance for clients across health specialties. He originally joined the agency in 2021 as business strategy director for the region. Prior to this, he was planning director at Publicis Groupe, group head of planning at Brandcare and co-founder of bolohealth.com.
Bedrock Healthcare Communications
Laura Wilson
Bedrock Healthcare Communications has appointed Laura Wilson as head of commercial strategy. Wilson joined Bedrock last year as client strategy director. Prior to that, she was commercial director, EU at Nucleus Global, after joining the agency as associate commercial director. She also previously worked at SciMentum, Saatchi & Saatchi Wellness, Adelphi Communications and Epistem.
Envision Pharma Group
Tino Quintero
Envision Pharma Group has appointed Tino Quintero as general manager/vice president of market access and customer insights. Quintero brings more than 25 years of experience as a biopharma and life sciences executive. He joins Envision from The Q Group, where he served as consultant and executive coach. Prior to this, he was chief commercial officer at Locus Biosciences.
CultHealth
David Stemler
CultHealth has appointed David Stemler as chief creative officer. Stemler joins the agency with close to 15 years of marketing and creative experience in the life sciences sector. He was most recently executive creative director at CDM New York – part of the Omnicom Health Group – after spending the first 11 years of his career at health creative agency The Bloc. He also worked at The Huffington Post.
Aurora
Bettina Seri
Aurora has appointed Bettina Seri as director and head of medical communications. Following a career in academia, Seri gained more than 14 years’ experience in medical education and communications at a number of London-based agencies. This included senior strategic roles at MKG Global, ApotheCom and, most recently, Pollen Health, where she was scientific strategy and business director.
Aurora
Stephen O’Farrell
Aurora has appointed Stephen O’Farrell as director and head of patient engagement. O’Farrell originally joined the agency in 2015 and, following 18 months as a senior consultant at Wilson Hartnell in Dublin, he now rejoins Aurora’s leadership team to further develop its patient engagement offering. He started his career as a news journalist, before joining patient group Arthritis Ireland in 2011 as communications executive.
Innovative Trials
Eloise Moffett
Innovative Trials has appointed Eloise Moffett as vice president of commercial. Moffett joins the agency with more than 20 years of experience in business development, the last five of which have been spent specialising in clinical trial patient retention. She was most recently senior vice president of business development at mdgroup, having originally joined the company as business development manager.
KVA
Chris Chappell
KVA has appointed Chris Chappell as executive creative director. Chappell joins the agency with over 20 years of experience in campaign creation, interactive design and art direction. He has been leading the creative at Ogilvy Health for over a decade, most recently as executive creative director, for a wide range of clients such as AstraZeneca, Bayer, BMS, GSK, Pfizer and Roche. He has also been executive creative director at apio.
Onyx Health
Laura Waldron
Onyx Health has appointed Laura Waldron as account manager. Waldron brings over five years of industry experience to her new role. She was most recently digital marketing manager at Slater Heelis, after joining the law firm at the beginning of 2020 as digital marketing executive. Prior to this, she was digital content executive at ActiveWin Media, a role she took on after joining the company in 2018 as junior content executive.
Onyx Health
Katy Johns
and Lewis Hutchinson
Onyx Health has appointed Katy Johns as creative artworker and Lewis Hutchinson as marketing communications trainee. Johns joins the design team with extensive experience as a creative artworker and a keen ability to create engaging visual content. Hutchinson takes on the role alongside his ongoing CIM studies, marking his first step towards a career in healthcare marketing.
CREATION.co
Cameron Bassindale
and Aman-Rai Jandu
CREATION.co has appointed Cameron Bassindale and Aman-Rai Jandu as graduate research executives. Bassindale has been a freelance contributor at The Japan Society since December 2021 and an English language instructor at NOVA Co since March 2022. Jandu has served as client and systems support administrator at design and development company FLUID7 since September 2017.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services